Insmed (MIL:1INSM) Stock Based Compensation: €137.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1INSM Insmed Inc MIL:1INSM
45 GF Score
Price €86.10
GF Value €163.31
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Stock Based Compensation?

Insmed MIL:1INSM 45 Stock Based Compensation is €137.0 Mil as of Mar. 2026. GuruFocus rates MIL:1INSM with a GF Score™ of 45/100 and a GF Value™ of €163.31 (Possible Value Trap). The stock has 4 warning signs investors should review.

Insmed's Stock Based Compensation for the three months ended in Mar. 2026 was €39.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €137.0 Mil.

Insmed Stock Based Compensation Related Terms

Insmed Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Insmed's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Stock Based Compensation Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.73 54.46 68.57 92.48 130.41

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.32 37.26 26.78 33.34 39.58
MIL:1INSM
45GF Score
Insmed Inc MIL:1INSM
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €137.0 Mil.

What does a Stock Based Compensation of €137.0 Mil mean?
Insmed (MIL:1INSM) has a Stock Based Compensation of €137.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Insmed and its competitors.
Is Insmed's Stock Based Compensation too high?
Insmed's current Stock Based Compensation is €137.0 Mil. Overall, Insmed has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Stock Based Compensation compare to INCY and BNTX?
Insmed's Stock Based Compensation of €137.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Insmed and its competitors. Insmed's current Stock Based Compensation is €137.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MIL:1INSM) is currently considered Possible Value Trap. The stock's GF Value™ is €163.31, compared to a current price of €86.10 — trading 47.3% below its estimated fair value. The current Stock Based Compensation is €137.0 Mil. Insmed's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Insmed (MIL:1INSM), the current Stock Based Compensation is €137.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MIL:1INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €86.10 is trading 47.3% below its estimated GF Value™ of €163.31. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for MIL:1INSM:

  • Stock Based Compensation: €137.0 Mil
  • GF Value™: €163.31 vs. price of €86.10 (47.3% below fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the MIL:1INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Other Exchanges INSM:USA0JAV:UKIM8N:Germany
Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
45GF Score

Get the complete analysis for MIL:1INSM

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€86.10
Price
€163.31
GF Value